M. Wygrecka (Gießen, Germany), C. Vancheri (Catania (CT), Italy), N. Kahn (Heidelberg, Germany), M. Funke-Chambour (Bern, Switzerland)
Transcriptome profiling reveals the complexity of pirfenidone effects in IPF.
. Kwapiszewska (Graz , Austria), A. Gungl (Graz , Austria), J. Wilhelm (Giessen, Germany), L. Marsh (Graz, Austria), H. Thekkekara Puthenparampil (Graz, Austria), K. Sinn (Vienna, Austria), M. Didiasova (Giessen, Germany), W. Klepetko (Vienna, Austria), D. Kosanovic (Giessen, Germany), R. Schermuly (Giessen, Germany), L. Wujak (Giessen, Germany), B. Weiss (Giessen, Germany), L. Schaefer (Frankfurt am Main, Germany), M. Schneider (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), A. Olschewski (Graz, Austria), W. Seeger (Giessen, Germany), H. Olschewski (Graz, Austria), M. Wygrecka (Giessen, Germany)
|  |
Characterization of Mesenchymal Stem Cells obtained from human lungs with and without Idiopathic Pulmonary Fibrosis
A. Jahn (Palma, Spain), C. Rio (Palma, Spain), A. Montes (L'Hospitalet de Llobregat, Spain), P. Pont (Palma, Spain), J. Mercader (Palma, Spain), J. Velasco (Palma, Spain), C. Gómez (Palma, Spain), C. Villena (Palma, Spain), Á. Carvajal (Palma, Spain), O. Gigirey (Palma, Spain), M. Molina (L'Hospitalet de Llobregat, Spain), E. Sala (Palma, Spain)
| |
Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib
W. Gan (Tianjin, China), K. Huang (Tianjin, China), Z. Lv (Tianjin, China), S. Gao (Tianjin, China), C. Su (Tianjin, China), X. Li (Tianjin, China), H. Zhou (Tianjin, China)
| |
Growth hormone releasing hormone receptor (GHRH-R) antagonist MIA-602 modulates fibrosis and gene expression in lungs of bleomycin-treated mice
R. Jackson (Miami, United States of America), C. Zhang (Miami, United States of America), G. Delcroix (Miami, United States of America), T. Cui (Miami, United States of America), X. Zhang (Miami, United States of America), M. Mirsaeidi (Miami, United States of America), A. Lazerson (Miami, United States of America), A. Schally (Miami, United States of America)
|  |
Pulmonary fibrosis modulation by mesenchymal stem cells and conditioned medium
R. Goncalves Felix (BOTUCATU, Brazil), A. Carvalho Bovolato (BOTUCATU, Brazil), P. Dos Santos Leão (RIBEIRÃO PRETO, Brazil), M. De Assis Golim (BOTUCATU, Brazil), W. Rosolia Teodoro (SÃO PAULO, Brazil), A. Todorovic Fabro (RIBEIRÃO PRETO, Brazil), E. Deffune (BOTUCATU, Brazil), V. Luiza Capelozzi (SÃO PAULO, Brazil)
| |
Cigarette Smoke Extract Promotes Human Lung Myofibroblast Differentiation by the Induction of Endoplasmic Reticulum Stress
M. Song (Changsha, China), H. Peng (Changsha, China), W. Guo (Changsha, China), M. Luo (Changsha, China), W. Duan (Changsha, China), P. Chen (Changsha, China), Y. Zhou (Birmingham, United States of America)
| |
Dual aVß6/aVß1 inhibitor PLN-74809 blocks multiple TGF-ß activation pathways associated with IPF
M. Decaris (South San Francisco, United States of America), J. Schaub (South San Francisco, United States of America), C. Chen (South San Francisco, United States of America), J. Cha (South San Francisco, United States of America), M. Reilly (South San Francisco, United States of America), G. Lee (South San Francisco, United States of America), M. Rexhepaj (South San Francisco, United States of America), V. Rao (South San Francisco, United States of America), P. Kotak (South San Francisco, United States of America), L. Hooi (South San Francisco, United States of America), J. Wu (South San Francisco, United States of America), S. Martin (South San Francisco, United States of America), T. Chen (South San Francisco, United States of America), M. Munoz (South San Francisco, United States of America), N. Cooper (South San Francisco, United States of America), T. Hom (South San Francisco, United States of America), K. Leftheris (South San Francisco, United States of America), P. Andre (South San Francisco, United States of America), E. Gorina (South San Francisco, United States of America), E. Lefebvre (South San Francisco, United States of America), S. Turner (South San Francisco, United States of America)
| |
Cadmium exposure, citrullinated vimentin and lung fibrosis. Veena B. Antony1MD, Ranu Surolia1, PhD, A. Brent Carter1, MD, and Fu Jun Li1MD, PhD. University of Alabama at Birmingham, Birmingham, AL, USA
V. Antony (Birmingham, United States of America), R. Surolia (Birmingham, United States of America), A. Carter (Birmingham, United States of America), F. Li (Birmingham, United States of America)
| |
TRPA1 ion channel expression in human lung myofibroblasts
H. Virk (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), V. Bowman (Leicester, United Kingdom), C. Feghali-Bostwick (Charleston, United States of America), Y. Amrani (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom), K. Roach (Leicester, United Kingdom)
| |
Role of transient receptor potential vanilloid 4 in the therapeutic antifibrotic effects of pirfenidone
K. Kuronuma (Sapporo, Japan), M. Otsuka (Sapporo, Japan), M. Wakabayashi (Toyonaka, Japan), T. Yoshioka (Toyonaka, Japan), Y. Morioka (Toyonaka, Japan), T. Kobayashi (Sapporo, Japan), M. Kameda (Sapporo, Japan), H. Chiba (Sapporo, Japan), H. Takahashi (Sapporo, Japan)
| |
Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis
A. Egan (Rochester, United States of America), M. Ali (Rochester, United States of America), G. Shaughnessy (Rochester, United States of America), H. Dasari (Montreal, Canada), V. Van Keulen (Rochester, United States of America), T. Peikert (Rochester, United States of America), E. Carmona Porquera (Rochester, United States of America)
| |
Interstitial lung disease related surfactant protein-C mutations alter the transcriptome and progenitor cell function of alveolar epithelial cells in mice
J. Katzen (Philadelphia, United States of America), A. Venosa (Philadelphia, United States of America), Y. Tomer (Philadelphia, United States of America), M. Kopp (Philadelphia, United States of America), M. Morely (Philadelphia, United States of America), A. Diwadkar (Philadelphia, United States of America), E. Morrisey (Philadelphia, United States of America), B. Himes (Philadelphia, United States of America), S. Mulugeta (Philadelphia, United States of America), M. Beers (Philadelphia, United States of America)
| |
The cross-talk between TGF-ß and periostin can be targeted for pulmonary fibrosis
Y. Nanri (SAGA, Japan), S. Nunomura (SAGA, Japan), Y. Terasaki (Tokyo, Japan), T. Yoshihara (SAGA, Japan), Y. Hirano (SAGA, Japan), Y. Yokozaki (Hiroshima, Japan), K. Ajito (Yokohama, Japan), S. Murakami (Yokohama, Japan), S. Conway (Indianapolis, Indiana, United States of America), K. Izuhara (SAGA, Japan)
| |
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
G. Lee (Seongnam, Republic of Korea), S. Kang (Seongnam, Republic of Korea), J. Ryou (Seongnam, Republic of Korea), J. Lim (Seongnam, Republic of Korea), Y. Lee (Seongnam, Republic of Korea)
| |
An electronic nose can sniff out idiopathic pulmonary fibrosis.
S. Dragonieri (bari, Italy), D. Lacedonia (foggia , Italy), I. Caccavo (foggia , Italy), P. Carratu (bari, Italy), G. Carpagnano (foggia, Italy), T. Ranieri (bari , Italy), M. Foschino Barbaro (foggia, Italy), O. Resta (bari , Italy)
| |
Late Breaking Abstract - Il24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing the m2 program in macrophages
L. Rao (Guilin, China), L. Luo (Guilin, China), B. Mo (Guilin, China)
| |
Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis
T. Ogura (Kanagawa, Japan), Y. Nishioka (Tokushima, Japan), T. Saito (Ibaraki, Japan), K. Tomii (Hyogo, Japan), K. Kamio (Tokyo, Japan), H. Tomioka (Hyogo, Japan), S. Hisata (Tochigi, Japan), S. Sakamoto (Tokyo, Japan), T. Handa (Kyoto, Japan), Y. Miyazaki (Tokyo, Japan), S. Homma (Tokyo, Japan), A. Azuma (Tokyo, Japan)
| |
Late Breaking Abstract - High cumulative dose of allogeneic mesenchymal stem cells in patients with progressive idiopathic pulmonary fibrosis
A. Averyanov (Moscow, Russian Federation), A. Sotnikova (Moscow, Russian Federation), I. Koroleva (Moscow, Russian Federation), M. Konoplyannikov (Moscow, Russian Federation), O. Danilevskaya (Moscow, Russian Federation), V. Lesnyak (Moscow, Russian Federation), V. Baklaushev (Moscow, Russian Federation)
| |
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis
S. Turner (South San Francisco, United States of America), E. Lepist (South San Francisco, United States of America), F. Rock (South San Francisco, United States of America), M. Decaris (South San Francisco, United States of America), J. Schaub (South San Francisco, United States of America), C. Chen (South San Francisco, United States of America), E. Gorina (South San Francisco, United States of America), E. Lefebvre (South San Francisco, United States of America)
| |
Late Breaking Abstract - Caveolin-1 derived peptide LTI-03 promotes epithelial cell survival and attenuates pulmonary fibrosis
B. MacKenzie (Austin, United States of America), V. Gopal (Tyler, United States of America), L. Fan (Tyler, United States of America), E. Maier (Austin, United States of America), Y. Zhang (Austin, United States of America), R. Wasnick (Giessen, Germany), A. Günther (Giessen, Germany), R. Williams 3rd (Austin, United States of America), S. Shetty (Austin, United States of America)
| |